Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoTSE:4527 -1.72%92 PS Ratio is 1.64 as of Jul. 21, 2026, which is 18% below its 10-year median of 2.01. GuruFocus rates TSE:4527 with a GF Score™ of 92/100 and a GF Value™ of 円3,477.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,943 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks worse than 71.18% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rohto Pharmaceutical Co's share price is 円2435.00.
Rohto Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,483.52. Hence, Rohto Pharmaceutical Co's PS Ratio for today is 1.64.
The historical rank and industry rank for Rohto Pharmaceutical Co's PS Ratio or its related term are showing as below:
TSE:4527'
s PS Ratio Range Over the Past 10 Years
Min: 1.08 Med: 2.01 Max: 3.75
Current: 1.64
During the past 13 years, Rohto Pharmaceutical Co's highest PS Ratio was 3.75. The lowest was 1.08. And the median was 2.01.
TSE:4527's PS Ratio is ranked worse than 71.18% of 1943
companies
in the Consumer Packaged Goods industry
Industry Median: 0.86
vs TSE:4527: 1.64
Rohto Pharmaceutical Co Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Rohto Pharmaceutical Co was 8.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year.
During the past 13 years, Rohto Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 15.60% per year. The lowest was 1.80% per year. And the median was 5.55% per year.
Back to Basics: PS Ratio
Rohto Pharmaceutical Co (TSE:4527) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Rohto Pharmaceutical Co's Share Price of today is 円2435.00. Rohto Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,483.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Rohto Pharmaceutical Co (TSE:4527) has a PS Ratio of 1.64 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Rohto Pharmaceutical Co and its competitors. This is 18% below median its historical median of 2.01. Over the past decade, Rohto Pharmaceutical Co's PS Ratio has ranged from 1.08 to 3.75. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #1383 out of 1943 companies in the Consumer Packaged Goods industry, placing it in the top 71.2%.
Is Rohto Pharmaceutical Co's PS Ratio too high?
Rohto Pharmaceutical Co's current PS Ratio of 1.64 is 18% below median its 10-year median of 2.01. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 3.75. The Consumer Packaged Goods industry median PS Ratio is 0.86. Rohto Pharmaceutical Co's value of 1.64 is 90.7% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #1383 out of 1943 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's PS Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #1383 out of 1943 companies for PS Ratio. This places Rohto Pharmaceutical Co in the lower half of its industry. The industry median PS Ratio is 0.86. Rohto Pharmaceutical Co's value of 1.64 is 90.7% above this benchmark. Historically, Rohto Pharmaceutical Co's own PS Ratio has ranged from 1.08 to 3.75 over the past decade. While the company's 10-year median is 2.01 vs. the industry median of 0.86, Rohto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Consumer Packaged Goods company?
The median PS Ratio among Consumer Packaged Goods companies is 0.86, based on 1,943 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current PS Ratio of 1.64 is 90.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median PS Ratio is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current PS Ratio is 1.64, which is 18% below median its own 10-year median of 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Significantly Undervalued. The stock's GF Value™ is 円3,477.35, compared to a current price of 円2,435.00 — trading 30% below its estimated fair value. The current PS Ratio is 1.64, which is 18% below median its 10-year median of 2.01 and 90.7% above the Consumer Packaged Goods industry median of 0.86. Rohto Pharmaceutical Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current PS Ratio is 1.64 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,435.00 is trading 30% below its estimated GF Value™ of 円3,477.35.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TSE:4527:
PS Ratio: 1.64 (18% below median its 10-year median of 2.01)
GF Value™: 円3,477.35 vs. price of 円2,435.00 (30% below fair value)
Industry Position: 90.7% above the Consumer Packaged Goods median (#1383 of 1943)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
92GF Score
Get the complete analysis for TSE:4527
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
